BARCODE REVOLUTIONIZING PERSONALIZED
DIAGNOSTIC CANCER CARE - Choosing Right from the Beginning
Barcode Diagnostics is developing a unique, first-of-its-kind product that quickly and reliably assesses the efficacy of different cancer drugs directly on the tumor within the body to select the optimal personalized treatment for each patient.
Over 1.6M new cancer cases are diagnosed in the US each year. One of three patients does not receive the optimal treatment he or she deserves. Today, once a tumor is diagnosed, choice of treatment based on clinical signs manifested in similar cancer cases, which result in trial and error of multiple chemotherapy regimens.
Beyond the loss of valuable time and suffering for each individual patient, the financial burden of the wrong treatment choice in the US alone accounts for more than $10 Billion in direct costs annually.
Barcode Diagnostics is developing a “first of its kind” proprietary technology for personalized cancer drug screening, that quickly and reliably assesses the efficacy of different cancer drugs directly on the tumor within the patient’s own body.
From a clinical perspective, our aim is to provide physicians with a new tool that matches each patient with the most potent medicine, during the different stages of disease to improve cancer care.
Proof of concept for the technology was recently published in Nature communications [Yaari et al. 2016].
For a short video demonstration of the concept click here.
Personalized therapy is revolutionizing medical care. Barcode diagnostics’ unique technology strategically positions our company at the cutting edge of this new avenue. Our solution which directly assesses the efficacy of different compounds on the tumor inside the patient is expected to improve cancer treatment consequently effecting the financial aspects of clinical care.
The annual current cancer market in the US alone is estimated at over $200B. Personalized medicine aims to impact both the direct and indirect costs associated with cancer care.
The company holds an exclusive license for the IP (from the Technion). National applications filled worldwide. Additional patents will be submitted during the next 6-12 months.
Ronen Eavri Ph.D – CEO and Co-founder: Graduate of the Hebrew University and a post-doctoral fellowship at MIT. Over 5 years of experience leading product development in pharma and medical device companies (J&J and D-Pharm).
Annie Sabbah Ph.D – CTO and Co-founder: Graduate of the Technion- Israel Institute of Technology. Former Laboratory Research Manager at the Clinical Research Institute of Rambam Medical Care Campus and former CTO of MPT Diagnostics. Over 5 years of experience in the microparticles field. Expert in molecular biology.
Avi Schroeder Ph.D – Inventor, Co-founder and Scientific consultant: Assistant Professor, Faculty of Chemical Engineering Technion- Israel Institute of Technology. Co-founder and inventor - ViAqua Therapeutics, Moebius Medical, InPlant and PEEL Therapeutics.
Prof. Tamar Peretz-Yablonski - Scientific Advisory Board:
Head, Sharett Institute of Oncology. Director, Center for Malignant Breast Diseases. Lawrence Schachl Chair of Oncology. Hadassah Medical Center, Israel. World–renowned expert on breast cancer and clinical implications of cancer genomics, with over 250 publications in the field of oncology.
Dr. Shai Rosenberg - Medical Advisor:
Senior Neuro-Oncologist, - Hadassah Medical Center. M.D. Ph.D Technion Excellence Program. Post-doctoral fellowship - ICM Institute Salpêtrière Hospital - Paris. Computational biology and cancer genomics expert.
Zohar Gendler – Managing Partner & CEO – NGT3 Technological Incubator: Former CEO and director of Beta-O2 Technologies. Served as CEO of the Technion Entrepreneurial Incubator (TEIC) - 11 years. Led the establishment and investment in more than 40 companies including: Prolor Biotech, Mazor Robotics, ReWalk, Corindus, Regentis and many others.
The company is developing the first prototype including multiple drug candidates for detection of the optimal treatment option for one clinical indication.
The prototype is currently being preclinically tested for safety and efficacy. Following these studies, we are aiming at first-in-human clinical trials.
Ronen Eavri , CEO
Barcode Diagnostics at NGT3 Technological Incubator
P.O. Box 1252, Nazareth Illit 17111, Israel